LENSAR (LNSR) Stock Price, News & Analysis

Company Overview

LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens.

The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Based in Orlando, Florida, LENSAR serves eye surgeons and healthcare providers in the United States and international markets. The company was founded in 2004 and focuses on developing technology intended to support precision and workflow in cataract surgery.

Key Stats

• Today's Range: $4.68 to $5.00
• 50-Day Range: $4.58 to $8.60
• 52-Week Range: $4.30 to $12.94
• Volume: 17,091 shs
• Average Volume: 90,750 shs
• Market Capitalization: $59.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

LENSAR Stock Analysis - MarketRank™

LENSAR scored higher than 35% of companies evaluated by MarketBeat, and ranked 728th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

LENSAR has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

LENSAR has a consensus price target of $11.00, representing about 127.4% upside from its current price of $4.84.

Amount of Analyst Coverage

LENSAR has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LENSAR is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENSAR is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENSAR has a P/B Ratio of 5.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.29% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 6.77.

Change versus previous month

Short interest in LENSAR has recently decreased by 0.25%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENSAR does not currently pay a dividend.

Dividend Growth

LENSAR does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.27

News Sentiment

LENSAR has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for LENSAR this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENSAR insiders have not sold or bought any company stock.

Percentage Held by Insiders

65.80% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:LNSR
• CIK: 1320350
• Web: www.lensar.com
• Phone: 888-536-7271
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for LENSAR: $11.00
• High Price Target: $13.00
• Low Price Target: $9.00
• Potential Upside/Downside: +127.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.28 million
• Net Margins: 56.07%
• Pretax Margin: 56.07%
• Return on Equity: 1,254.25%
• Return on Assets: 49.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: $58.44 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 5.37

Miscellaneous

• Outstanding Shares: 12,290,000
• Free Float: 4,202,000
• Market Cap: $59.45 million
• Optionable: Optionable
• Beta: 1.03